LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRXBiotechnology
-$0.39 today
- Market cap
- $1.30B
- Beta
- 0.71
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.39
Volume 0.36M
Average 0.23M
LBRX Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
LB Pharmaceuticals Inc Common StockNASDAQ: LBRX
Total Assets · Q1 FY2026 · quarter ended Mar 2026
Total assets rises 1944.3% from a year ago
Total assets stood at $393.48M at the end of Q1 FY2026, up 1944.3% from a year earlier and up 25.7% from the prior quarter. Over 3 fiscal years it compounded at +144.2% a year.
Context
- Total assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total assets keeps rising in the next quarterly balance sheet after a +1944.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 312.93M USD
- Year-over-year change
- +833.2%
- 3-year CAGR
- +144.2%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 312.93M | +833.2% |
| FY2024 | 2024-12-31 | 33.53M | -26.6% |
| FY2023 | 2023-12-31 | 45.66M | +112.4% |
| FY2022 | 2022-12-31 | 21.49M | — |
Total Assets vs competitors
How LBRX compares with its peers on the latest reported figures
- LBRX's Mar 2026 total assets of $393.48M is the 7th highest of the 10 companies compared; the peer median is $497.6M.
- Its year-over-year change of +1944.3% is the 2nd highest of 10, against a peer median of +60.7%.
- Over three fiscal years its annual growth of +144.2% compares with a peer median of +37.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Jun 2026 | $95.09B | +312490.6% | +21.2% | |
| Sep 2026 | $1.79B | +34.8% | +38.6% | |
| Jun 2026 | $1.16B | -0.7% | -7.8% | |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $1.07B | +353.4% | +37.3% |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $497.6M | +64.7% | +153.1% |
| Mar 2026 | $418.79M | +275.4% | +130.0% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $393.48M | +1944.3% | +144.2% |
| Mar 2026 | $276.26M | +60.7% | +53.7% | |
| Mar 2026 | $275.27M | -14.1% | +4.3% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $153.88M | -40.1% | -23.5% |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — |
| Peer median (excluding LBRX) | $497.6M | +60.7% | +37.3% | |
Competitors are the stored peer set for LBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
Intrinsic Alpha fair value
Locked
Current Price
$40.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.